Thetis Pharmaceuticals

Latest news, clinical data, and company announcements from Thetis Pharmaceuticals. Updates on TP-317 development for IBD and cancer treatment.

Thetis Pharmaceuticals, LLC develops TP-317, an oral BLT1 agonist for IBD and cancer. The U.S. Patent and Trademark Office granted patent 12,564,644, covering its composition and use through March 2043, with possible extension to 2048.

ESSEX, Conn.— October 2, 2025—Thetis Pharmaceuticals, LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, oral, small molecule Resolvin E1 (RvE1) drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) and cancer, today announced the appointment

Findings Highlight First-in-Class Potential of TP-317 in Inflammatory Bowel Disease and Colorectal Cancer

Thetis is a biopharmaceutical company developing therapies for cancer and autoimmune diseases, founded by former Pfizer R&D executives and healthcare entrepreneurs.

Thetis Pharmaceuticals is a clinical-stage biotech developing first-in-class Resolvin E1 therapy. Backed by Helmsley Charitable Trust. Based in Essex, CT.

Contact Thetis Pharmaceuticals for business development, investor relations, and media inquiries. Based in Essex, Connecticut.

Phase 1a Clinical Results Demonstrate a Favorable Safety Profile and BLT1 Target Engagement In Healthy Volunteers ESSEX, Conn.--—April 9, 2025—Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 rec

Thetis Pharmaceuticals develops TP-317, a first-in-class oral BLT1 agonist based on Resolvin E1 for inflammatory bowel disease and solid tumor cancers.